Displaying 1 - 10 of 15 for Cancer - Lymphoma
  • CARPASCIO Study (H-33133)
    • The purpose of this study is to see whether this therapy might help people with lymphoma or leukemia after a stem cell transplantation from a donor.
  • CHARKALL Study (H-23574)
    • Patients have a type of cancer called NHL, Multiple Myeloma (MM) or CLL. The lymphoma, MM or CLL has come back or has not gone away after treatment. This is a gene transfer research study using special immune cells.
  • CITADEL-112 : Previously Treated B-Cell Lymphoma (H-43701)
    • The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.
  • ENGINE Study (H-43427)
    • This randomized, placebo-controlled phase 3 study is planned to enroll approximately 235 treatment-naïve subjects with high-risk Diffuse Large B-Cell Lymphoma (DLBCL).
  • GRALE Study (H-29617)
    • The purpose of this study is to find the largest safe dose of LMP-specific cytotoxic GRALE T cells created using this new manufacturing technique.
  • ICare: Improving Care for Cancer Survivors (H-43629)
    • This study addresses the need to clarify system, provider and survivor-level facilitators of survivorship care plans implementation/use to guide future rollout efforts.
  • MABEL Study (H-35253)
    • In this study, we want to find out if we can use banked MABEL CTLs to treat HD or NHL, T/NK-lymphoproliferative disease and severe chronic active Epstein Barr Virus (CAEBV).
  • MAGENTA Study (H-40466)
    • This research study combines antibodies and T cells to fight a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer).
  • MOHEL Study (H-8701)
    • Subjects are being asked to participate in this study because treatment of their disease requires them to receive a stem cell transplant.
  • NCI MATCH Screening Trial (H-37222)
    • This clinical trial studies how well treatment directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.